Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review

Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review

BackgroundCraniopharyngioma is a rare intracranial tumor, with a high morbidity rate due to its common refractiveness to conventional treatments. BRAF V600E mutation has recently been identified as the principal oncogenic molecular driver of papillary craniopharyngiomas (PCP), one of the two main va...

Full description

Bibliographic Details
Main Authors:	Morena Fasano, Carminia Maria Della Corte, Marianna Caterino, Mario Pirozzi, Raffaele Rauso, Teresa Troiani, Giulia Martini, Stefania Napolitano, Floriana Morgillo, Fortunato Ciardiello
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-01-01
Series:	Frontiers in Medicine
Subjects:	craniopharyngioma BRAF BRAF mutation V600E targeted dabrafenib trametinib
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2021.652005/full

Similar Items

Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma
by: David Balakirouchenane, et al.
Published: (2020-04-01)

RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation
by: Baptiste Le Calvez, et al.
Published: (2020-07-01)

Efficacy of dabrafenib/trametinib in pancreatic ductal adenocarcinoma with BRAF NVTAP deletion: A case report
by: Ji Eun Shin, et al.
Published: (2022-11-01)

The Pattern of Progression to First-Line Treatment with Dabrafenib and Trametinib in Patients with Unresectable or Metastatic, BRAF-Mutated, Cutaneous Melanoma: Results of the Observational T-WIN Study
by: Michele Del Vecchio, et al.
Published: (2023-03-01)

Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma
by: Walid Shalata, et al.
Published: (2023-02-01)

Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy
by: Weart TC, et al.
Published: (2018-04-01)

Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort studyResearch in context
by: Xue Bai, et al.
Published: (2023-11-01)

A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III)
by: Victoria G. Atkinson, et al.
Published: (2021-05-01)

Case report: Dual dabrafenib and trametinib therapy for treating BRAF V600E mutated lung adenocarcinoma with BRCA2 germline mutation post multiline progression
by: Huimin Zhang, et al.
Published: (2024-04-01)

COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma
by: Carola Berking, et al.
Published: (2023-09-01)

Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAFV600E mutated, microsatellite-stable colon cancer: A case report and literature review
by: Gudrun Piringer, et al.
Published: (2023-05-01)

Effectiveness Treatment of a BRAF-ZKSCAN5 Fusion Gene Melanoma Case with Dabrafenib/Trametinib
by: Hiroshi Kato, et al.
Published: (2023-09-01)

Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma
by: Wei Wang, et al.
Published: (2021-09-01)

Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report
by: Yuta Adachi, et al.
Published: (2020-02-01)

Durable Response to Combined Dabrafenib and Trametinib in a Patient With BRAF K601E Mutation-Positive Lung Adenocarcinoma: A Case Report
by: Po-Lan Su, MD, et al.
Published: (2021-08-01)

An advanced pulmonary sarcomatoid carcinoma patient harboring a BRAFV600E mutation responds to dabrafenib and trametinib: a case report and literature review
by: Ruoxin Fang, et al.
Published: (2023-07-01)

Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma
by: Nora Isberner, et al.
Published: (2022-09-01)

Cerebral infarction after treatment with dabrafenib plus trametinib for BRAF‐V600E‐positive non–small cell lung cancer: A case report
by: Yoshihiko Taniguchi, et al.
Published: (2023-05-01)

Successful dabrafenib and trametinib combination therapy in a patient with recurrent BRAF V600E‐mutant non‐small‐cell lung cancer and coexisting radiation pneumonitis
by: Eriko Nakamura, et al.
Published: (2024-01-01)

Clinical Response of Advanced Lung Adenocarcinoma with Class III BRAF G466V Missense Mutation to Dabrafenib and Trametinib: A Case Report
by: Fang R, et al.
Published: (2024-01-01)

Combined Lorlatinib, Dabrafenib, and Trametinib Treatment for ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer with a Lorlatinib-Induced BRAF V600E Mutation: A Case Report
by: Li D, et al.
Published: (2022-11-01)

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
by: Ken Saijo, et al.
Published: (2022-08-01)

Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation
by: Bárbara Lima, et al.
Published: (2022-04-01)

BRAF Inhibitors in Non-Small Cell Lung Cancer
by: Vincenzo Sforza, et al.
Published: (2022-10-01)

BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
by: Karisa C. Schreck, et al.
Published: (2019-08-01)

Exceptionally long‐lasting response to dabrafenib plus trametinib treatment in a patient with lung adenocarcinoma harboring the BRAF V600E mutation with high expression of PD‐L1: A case report
by: Takako Inoue, et al.
Published: (2024-04-01)

Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution
by: Vincenzo Di Nunno, et al.
Published: (2023-01-01)

Response to the Combination of Osimertinib, Dabrafenib, and Trametinib in Leptomeningitis From EGFR-Mutant NSCLC With Acquired BRAF V600E Mutation: A Case Report
by: Orion Valet, et al.
Published: (2021-06-01)

Characteristics of Real-World Patients with High-Risk BRAFV600E/K-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program
by: Quaglino P, et al.
Published: (2023-11-01)

Non-small-cell lung cancer: how to manage BRAF-mutated disease
by: Giorgia Guaitoli, et al.
Published: (2023-05-01)

Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements
by: Alia Thawer, et al.
Published: (2021-09-01)

BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation
by: Stefanie Hoyer, et al.
Published: (2021-11-01)

Case report: Clinical success targeting BRAF-mutated, hormone receptor positive, HER2- negative advanced breast cancer patient with BRAF-inhibitor plus MEK- inhibitor
by: Alfonso López de Sá, et al.
Published: (2022-12-01)

Efficacy of Dabrafenib Plus Trametinib Combination in Patients with <em>BRAF</em> V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019
by: Jean-Bernard Auliac, et al.
Published: (2020-12-01)

Vemurafenib Combined With Trametinib Significantly Benefits the Survival of a Patient With Stage IV Pancreatic Ductal Adenocarcinoma With BRAF V600E Mutation: A Case Report
by: Ziyao Wang, et al.
Published: (2022-01-01)

Ocular toxicity due to Trametinib and Dabrafenib
by: Stephanie Sarny, et al.
Published: (2017-08-01)

Dabrafenib plus trametinib versus nivolumab for advanced melanoma
by: Daniela Lahoz, et al.
Published: (2023-02-01)

A Rare Case of Pituitary Melanoma Metastasis: A Dramatic and Prolonged Response to Dabrafenib-Trametinib Therapy
by: Marilda Mormando, et al.
Published: (2020-07-01)

BRAF L485–P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review
by: Simeng Zhang, et al.
Published: (2023-01-01)

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing
by: Gulietta M. Pupo, et al.
Published: (2017-05-01)